Harlan S. Robins - May 5, 2021 Form 4/A - Amendment Insider Report for Adaptive Biotechnologies Corp (ADPT)

Role
Chief Scientific Officer
Signature
/s/ Harlan Robins by Eric Billings, Attorney-in-Fact
Stock symbol
ADPT
Transactions as of
May 5, 2021
Transactions value $
-$227,815
Form type
4/A - Amendment
Date filed
6/11/2021, 09:00 PM
Date Of Original Report
May 7, 2021
Next filing
Jun 11, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADPT Common Stock Options Exercise $24.6K +3.9K +5.62% $6.32 73.3K May 5, 2021 Direct F1
transaction ADPT Common Stock Sale -$138K -3.9K -5.32% $35.43* 69.4K May 5, 2021 Direct F1, F2
transaction ADPT Common Stock Options Exercise $24.6K +3.9K +5.62% $6.32 73.3K May 6, 2021 Direct F1
transaction ADPT Common Stock Sale -$108K -3.05K -4.16% $35.51* 70.2K May 6, 2021 Direct F1, F3
transaction ADPT Common Stock Sale -$30.8K -847 -1.21% $36.38* 69.4K May 6, 2021 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ADPT Stock Option (Right to Buy) Options Exercise $0 -3.9K -2.86% $0.00 132K May 5, 2021 Common Stock 3.9K $6.32 Direct F1, F5
transaction ADPT Stock Option (Right to Buy) Options Exercise $0 -3.9K -2.94% $0.00 129K May 6, 2021 Common Stock 3.9K $6.32 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.
F2 The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $35.18 to 35.88, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3 The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $34.97 to 35.95, inclusive.
F4 The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $35.99 to 36.70, inclusive.
F5 The option is fully vested and exercisable.